459434-39-0 Usage
General Description
3-Amino-N-cyclopropylbenzenesulfonamide is a chemical compound often utilized in the pharmaceutical and chemical industry for its useful properties. It belongs to the category of organic compounds known as benzenesulfonamides, characterized by a benzenesulfonamide moiety, which consists of a benzene fused to a sulfonamide group. These types of compounds are known to have various biological activities, including antibacterial, diuretic, and antidiabetic properties. This specific sulfonamide, 3-Amino-N-cyclopropylbenzenesulfonamide, contains an aromatic benzene ring and a cyclopropyl group incorporated in its molecular structure. However, detailed pharmacological information about this specific compound is limited. As with all chemicals, appropriate safety measures should be taken while handling to avoid possible hazards.
Check Digit Verification of cas no
The CAS Registry Mumber 459434-39-0 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 4,5,9,4,3 and 4 respectively; the second part has 2 digits, 3 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 459434-39:
(8*4)+(7*5)+(6*9)+(5*4)+(4*3)+(3*4)+(2*3)+(1*9)=180
180 % 10 = 0
So 459434-39-0 is a valid CAS Registry Number.
InChI:InChI=1/C9H12N2O2S/c10-7-2-1-3-9(6-7)14(12,13)11-8-4-5-8/h1-3,6,8,11H,4-5,10H2
459434-39-0Relevant articles and documents
SUBSTITUTED AMIDE COMPOUNDS USEFUL AS FARNESOID X RECEPTOR MODULATORS
-
Page/Page column 105; 106, (2020/08/28)
Disclosed are compounds of Formula (I): or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt or solvate thereof, wherein Q is: (i) halo, cyano, hydroxyl, NRxRx, C(O)OH, C(O)NH2, C1-6 alkyl substituted with zero to 6 R1a, or P(O)R1cR1c; or (ii) L R1; and A, X1, X2, X3, X4, Z1, Z2, R1, R1a, R1c, R2, R3a, R3b, Rx, L, a, b, and d are defined herein. Also disclosed are methods of using these compounds to modulate the activity of farnesoid X receptor (FXR); pharmaceutical compositions comprising these compounds; and methods of treating a disease, disorder, or condition associated with FXR dysregulation, such as pathological fibrosis, transplant rejection, cancer, osteoporosis, and inflammatory disorders, by using the compounds and pharmaceutical compositions.
POTENT DUAL BRD4-KINASE INHIBITORS AS CANCER THERAPEUTICS
-
Page/Page column 142, (2016/04/26)
Disclosed herein are compounds that are inhibitors of BRD4 and their use in the treatment of cancer. Methods of screening for selective inhibitors of BRD4 are also disclosed. In certain aspects, disclosed are compounds of Formula I-IV.
